Loading...
•
Dec 31, 2021
Paysign Q4 2021 Earnings Report
Paysign's Q4 2021 financial results were reported, showing improved load volumes and spending trends approaching pre-pandemic levels.
Key Takeaways
Paysign reported positive Q4 results with improving revenues, income from operations, EBITDA, and adjusted EBITDA. The balance sheet also improved sequentially. The company is optimistic about growth prospects in plasma, pharma, and other prepaid businesses.
Load volumes and spending trends improved, nearing pre-pandemic levels.
Strategic priorities are being executed, with new deals in plasma and pharma.
The team and technology are being built out to handle future opportunities.
Revenues, income from operations, EBITDA, and adjusted EBITDA all improved both sequentially and year over year.
Forward Guidance
For the full year 2022, Paysign expects total revenue to be in the range of $35.25 million to $38.35 million, reflecting growth of 20% to 30%, with plasma making up approximately 90% of total revenue. Pharma revenue is expected to be relatively flat year over year as the loss of programs and settlement income in 2021 are offset with new pharma copay programs. Adjusted EBITDA is expected to at least double to $4.0 million over 2021’s adjusted EBITDA of $2.0 million.
Positive Outlook
- Total revenue is expected to grow by 20% to 30%.
- Plasma is expected to make up approximately 90% of total revenue.
- Adjusted EBITDA is expected to at least double to $4.0 million.
- Full year gross profit margins are expected to be approximately 50.0% to 52.5%.
- Company continues to make investments in people and technology.
Challenges Ahead
- Pharma revenue is expected to be relatively flat year over year.
- Loss of programs and settlement income in 2021 are offset with new pharma copay programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...